Geron (GERN) Q2 2024 earnings summary

Executive summary

• RYTELO (imetelstat) received FDA approval on June 6, 2024, as the first and only telomerase inhibitor for lower-risk MDS, and launched commercially in the U.S. in June 2024, with approximately 160 patients treated by July 31, 2024.

• NCCN Guidelines were updated to include RYTELO as a Category 1 and 2A treatment for lower-risk MDS, expanding its clinical adoption.

• Early launch metrics show strong uptake, with 60% of top decile accounts reached and broad engagement across community and academic settings.

• EU Marketing Authorization Application review for RYTELO is ongoing, with a decision expected in early 2025.

• The company is advancing imetelstat in myelofibrosis, with the Phase 3 IMpactMF trial ~70% enrolled and interim analysis expected in early 2026.

Financial highlights

• Q2 2024 net product revenue was $780,000, with total revenues of $882,000, up from $29,000 in Q2 2023, driven by initial RYTELO sales.

• Net loss for Q2 2024 was $67.4 million ($0.10/share), compared to $49.2 million ($0.09/share) in Q2 2023; six-month net loss was $122.8 million ($0.19/share).

• Operating expenses for Q2 2024 were $70.2 million, up from $52.0 million in Q2 2023, reflecting higher commercial launch costs and increased headcount.

• R&D expenses for Q2 2024 were $30.8 million, down from $35.5 million in Q2 2023; SG&A expenses rose to $39.4 million.

• Cash, cash equivalents, and marketable securities totaled $430.4 million as of June 30, 2024.

Outlook and guidance

• 2024 total operating expenses are expected to be $270–$280 million, including non-cash items.

• Existing cash and projected RYTELO revenues are expected to fund operations into Q2 2026.

• Permanent J-code for RYTELO is anticipated in Q1 2025, with national payer coverage expected in the same timeframe.

• Management expects product revenues to increase through the remainder of 2024 as the RYTELO launch progresses.

• Employee headcount projected to grow to 230–260 by year-end 2024.